Wolfgang Miesbach: Adenoassociated Virus-Based Gene Therapy for Haemophilia
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Gene Therapy for Haemophilia: From Experimental Concept to Clinical Reality. Written by young investigators (haematologists and hepatologists), for young investigators. Delighted to share the new educational review published in the Journal of Thrombosis and Haemostasis (JTH), providing a comprehensive overview of adenoassociated virus (AAV)-based gene therapy for haemophilia:
- Clinical Efficacy Demonstrated:
Phase III trials of valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (haemophilia B) have shown durable factor expression for up to 5 years, with persons with haemophilia achieving factor levels in the normal or mild haemophilia range and significant reductions in bleeding rates. The FIX-Padua variant has proven particularly transformative, enhancing treatment efficacy 5- to 8-fold.
- Hepatological Considerations:
Approximately 20% to 90% of persons with haemophilia experience transaminase elevation postinfusion, requiring immunosuppressive management and close hepatologic monitoring. This underscores the essential role of hepatologists within the multidisciplinary care team and the importance of comprehensive liver health assessment prior to treatment.
- Future Directions:
Whilst AAV-based therapies represent a remarkable advance, several developments promise to further enhance outcomes: alternative vectors to address neutralising antibody limitations (expanding access for seropositive patients), enhanced factor variants for improved efficacy, and gene editing technologies including CRISPR-Cas9 for precise genetic correction.
- Critical Challenges Remain:
Long-term durability beyond 5 years, immune response management, standardised care pathways, and equitable global access require continued attention and collaborative research efforts.
Congratulations to Pascal Hoffmann, Niccolò Bitto, and Vincenzo La Mura.”
Title: Overview of gene therapy for hemophilia: questions and answers to navigate the innovation
Authors: Pascal Hoffmann, Niccolò Bitto, Vincenzo La Mura, Wolfgang Miesbach
Read the Full Article on Journal of Thrombosis and Haemostasis.
Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy